sage in the hills
27 Apr 2017
Given up here....... ......have we ? ......SAGE
Brown Bull
15 Feb 2016
Re: Oxford Nanapore To Float Late This Year A £1bn valuation means IP Group's 20% stake is worth £200m. The current market cap of IP Group is £560m.
Janissery
15 Feb 2016
Oxford Nanapore To Float Late This Year This should hopefully push the price up more than somewhat methinks ! [link]
lambrini girl
21 Jan 2016
Re: Sold >>sell..initial target 160..<<BANG ON!!
Carefully Does It
17 Jan 2016
Re: Why the drop? Market probably doesn't see any near term exits in these market conditions. Risk off too.Innovation won't stop along with birth of new industries.Have to look through the current turmoil to what's beyond.
Brown Bull
16 Jan 2016
Why the drop? It's difficult to think a trading update could be more upbeat than that issued by IPO on 12 Jan.But the SP has continued to fall like a stone. Why?
triceratops
24 Dec 2015
Diurnal float Got away today and is trading up a touch on little volume.I'll buy a small amount when I accumulate some cash in my ISA. It'll go in the high risk/huge potential return bucket!below is an extract from a proactive investor piece this morning;"It’s not the ideal backdrop for a stock market debut – the last day before the Christmas break.But Diurnal Group (LON
NL) appears to have got it spot on with shares racing to a premium in early trade.The speciality pharma company, a spin out from IP Group (LON:IPO), raised around £30mln from the AIM listing and will be valued at a touch over £75mln.The stock was placed with institutions at 144p, which suggests those who took part in the City whip-round will be very pleased as the shares are now changing hands for 151p each, albeit on minimal volumes.As well as the placing proceeds, Diurnal has agreed a £4.7mln, five-year loan convertible at the placing price. The funding is being provided by IP2IPO, IP’s original name and now the Monica for one of the incubator’s subsidiaries.Anyway, Diurnal is an interesting addition to the ranks of the pharma and biotech sector.It is focused on finding treatments for chronic hormonal diseases. Its lead drug, Infacort, has been developed to combat a conditio called n adrenal insufficiency, which is more commonly known as Addison’s Disease. It symptoms include weight loss, fatigue and muscle weakness.The drug, which is being used to treat children under six, is undergoing phase III clinical trials in Europe. So if all goes to plan, it could be authorised by the third quarter of 2017.It is unusual to see a company list with a drug so far along the regulatory pathway. Usually, biotechs will tap the market at the start of the clinical study programme and hope to partner a drug by phase II.Its second drug candidate, Chronocort, for congenital adrenal hyperplasia, is set to enter its final-stage trial in the first quarter of next year.The new funds infusion will help with the continued development of its two potential products.Diurnal has spotted market opportunities in the specialist endocrinology market worth up to US$11bn a year.How long then before this one catches the eye of an ambitious drug giant looking to replenish a pipeline that has slowed to a dribble because of patent expiries?"
Hugh from H Q
21 Apr 2015
Re: NAV per share growth This is a high roller, up to you old Chaps.Forward & on to a brighter tomorrow
Carefully Does It
16 Apr 2015
Re: NAV per share growth in time they will have to exit a few.
Willow67
16 Apr 2015
Re: NAV per share growth It's an entirely valid point and it's why I sold my shares a while back. I love what they do and I applaud them for raising part of their recent capital through an open offer rather than a placing, but at the end of the day I don't trust the management to not dilute shareholders to death by constantly issuing a ton of equity.There is an excellent book by William Thorndike called The Outsiders which I strongly recommend people read and gives some great guidance on what 'the best' CEO's do. They manage for EPS growth, not market cap growth. Too many companies just issue stock and on AIM you are either excluded or forced to put up more capital to avoid dilution. It's hard to manage for the real benefit of shareholders in a business like IP which almost by definition is building a bigger and bigger portfolio of IP and so needs more an more capital. But iI is worth thinking about as you could go round and round with capital raises on this stock and end up nowhere down the road
frusset
10 Mar 2015
Re: NAV per share growth BTW I'm long IPO, but I wouldn't want to hold too much.
frusset
10 Mar 2015
NAV per share growth I've calculated the growth from the IP Group plc Annual Results Release, 2014 HIGHLIGHTS.They give "Net assets increased to £526.2m (2013: £337.0m) "2014 ~ 2013"Weighted average number of ordinary shares for the purposes of diluted earnings per share"464,990,912 ~ 379,029,290526,200,000 / 464,990,912 ~ 337,000,000 / 379,029,290= approx 1.13 ~ 0.89increase = 0.24increase / 2013 NAVps = 0.24 / 0.89 = approx 27.28%To calculate incentive compensation, IP Group use 'Hard NAV', which was £315.5m, with 18.8% p.a. growth.Either I've made a right meal of it and the NAV per share figures are easy to find, or management want you to see the much bigger rise in Net assets (not per share), which would indicate contempt for shareholders and an empire-building attitude (as does issuing shares when there's no obvious network effect or other economy of scale).
schovald
14 Feb 2015
Re: Xeros - Might be what is driving thi... Maybe some of it is due to the general upsurge in interest for early-stage companies because of the publicity surrounding the launch of Woodford Patient Capital?
sage in the hills
13 Feb 2015
Re: Xeros - Might be what is driving this st... Exactly, Xeros also topped out recently, IP did not follow same pattern.There is some other underlying value growth as well as Xeros .... but what is it ?( It is certainly NOT Modern Water ........ )SAGE
Janissery
13 Feb 2015
Xeros - Might be what is driving this stock higher Apparently the Federal Government is granting tax breaks to Xeros - which is driving it's price up ....and just might be influencing IP's price ...but not by as much as IP had gone up in recent weeks surely?! ( IP has a big stake in Xeros )
